These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1582069)

  • 1. Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE.
    Sturfelt G; Nived O; Sjöholm AG
    Clin Exp Rheumatol; 1992; 10(3):241-7. PubMed ID: 1582069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus.
    Jonsson H; Sturfelt G; Mårtensson U; Truedsson L; Sjöholm AG
    Clin Exp Rheumatol; 1995; 13(5):573-80. PubMed ID: 8575134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis.
    Schifferli JA; Morris SM; Dash A; Peters DK
    Clin Exp Immunol; 1981 Dec; 46(3):557-64. PubMed ID: 7337980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
    Balestrieri G; Pagani D; Tincani A
    J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sera of patients with systemic lupus erythematosus on artificial immune complexes.
    Bányai A; Szabó G; Csongor J; Sonkoly I; Szegedi G
    Acta Med Hung; 1985; 42(1-2):51-7. PubMed ID: 4034337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
    Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement components, C1 activation and disease activity in SLE.
    Sturfelt G; Sjöholm AG; Svensson B
    Int Arch Allergy Appl Immunol; 1983; 70(1):12-8. PubMed ID: 6293980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple enzyme immunoassay for measurement of immune complex solubilization utilizing preformed peroxidase-antiperoxidase complexes.
    Johansson I; Sturfelt G; Truedsson L
    J Immunoassay; 1994 Nov; 15(4):393-409. PubMed ID: 7836544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.
    Aguado MT; Perrin LH; Miescher PA; Lambert PH
    Arthritis Rheum; 1981 Oct; 24(10):1225-9. PubMed ID: 7306225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced complement-mediated immune complex solubilization in leprosy patients.
    Ramanathan VD; Sharma P; Ramu G; Sengupta U
    Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential studies of complement activation in systemic lupus erythematosus.
    Sturfelt G; Johnson U; Sjöholm AG
    Scand J Rheumatol; 1985; 14(2):184-96. PubMed ID: 4001891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosus.
    Larsen ML; Troldborg A; Toonen EJM; Hurler L; Prohaszka Z; Cervenak L; Gudmann Hansen A; Thiel S
    Clin Exp Immunol; 2023 Dec; 214(1):18-25. PubMed ID: 37407023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement components, complement activation, and acute phase response in systemic lupus erythematosus.
    Sturfelt G; Sjöholm AG
    Int Arch Allergy Appl Immunol; 1984; 75(1):75-83. PubMed ID: 6086533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-mediated solubilization of immune complexes and their interaction with complement C3 receptors.
    Petersen I; Baatrup G; Jepsen HH; Svehag SE
    Complement; 1985; 2(2-3):97-110. PubMed ID: 2935361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative complement pathway in hypocomplementemic/normal C1s-C1 inhibitor complex patients with SLE.
    Levy RA; Qamar T; Lockshin MD
    Clin Exp Rheumatol; 1990; 8(1):11-5. PubMed ID: 2347130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydralazine and isoniazid reduce the formation of soluble immune complexes by complement.
    Schifferli JA
    Immunol Lett; 1985; 9(5):297-9. PubMed ID: 3997205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
    Sturfelt G; Sjöholm AG; Truedsson L
    Immunol Lett; 1989 Feb; 20(3):231-6. PubMed ID: 2714846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.